secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kezar Life Sciences, Inc. (KZR)
CIK:        0001645666
Form:       8-K
Filed at:   2023-07-26T23:59:59+00:00
Accession:  0000950170-23-034761
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Kezar Life Sciences reprices executive stock options to $2.28
-------------------------------------------------------------

- Compensation Committee approved repricing of 2018 Plan options to $2.28/share, the July 24 closing price.
- CEO John Fowler: 2,655,000 options repriced from $3.29-$22.85; CFO Marc Belsky: 765,000 options.
- CMO Noreen Roth Henig (980,000 options) and Strategic Advisor Christopher Kirk (832,500) included.
- Repricing excludes options under the 2015 Plan and 2022 Inducement Plan; all other terms unchanged.
- Purpose: retain key contributors and preserve cash without additional equity dilution.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645666/000095017023034761/0000950170-23-034761-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645666/000095017023034761/kzr-20230724.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-034761

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer